Heterogeneity of contemporary grade group 4 prostate cancer in radical prostatectomy specimens
Alberto Martini(The University of Texas MD Anderson Cancer Center), Guillaume Ploussard(Yves Rocher (France)), Alae Touzani, A. Ruffion(Université de Lyon), Charles Dariane(Sorbonne Université), Jean‐Baptiste Beauval, Marc‐Olivier Timsit(Université Paris Cité), M. Roumiguié(Institut universitaire du cancer de Toulouse Oncopole), Raphaële Renard‐Penna(Sorbonne Université), M. Thoulouzan(Hôpital Rangueil), Arnauld Villers(Université de Lille), Gaëlle Fromont(Centre Hospitalier Universitaire de Tours), G. Créhange(Centre Georges François Leclerc), A. Gasmi(Centre Hospitalier Universitaire de Rennes), Mathieu Gauthé(Inserm), Morgan Rouprêt(Sorbonne Université), Guilhem Roubaud(Institut Bergonié), Jonathan Olivier(Université de Lille), Romain Mathiéu(Centre Hospitalier Universitaire de Rennes), G. Fiard(Centre Hospitalier Universitaire de Grenoble), L. Brureau(Institut de Recherche en Santé, Environnement et Travail), Éric Barret(Institute Mutualiste Montsouris), Paul Sargos
Cited by 5
Related Papers
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
|The Lancet Oncology|2014|451
Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins
|The Journal of Urology|2012|359
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2023|332